Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Pfizer Inc. is conducting a Phase 1 study titled ‘A Phase 1, Open-label, Fixed Sequence, 2-period Study in Healthy Adult Male Participants to Assess the Mass Balance, Absolute Bioavailability, Fraction Absorbed, and Pharmacokinetics of [14C]PF-07104091.’ The study aims to understand how the body processes the investigational drug PF-07104091, focusing on its absorption, distribution, metabolism, and excretion in healthy adult males.
The study involves two experimental interventions where participants will receive oral doses of PF-07104091, with the second phase including an intravenous infusion of a microdose of the radiolabeled drug. This approach helps determine how the drug is absorbed into the bloodstream and its subsequent processing by the body.
The study is designed as an open-label, single-group assignment with no masking, primarily for basic scientific exploration. Participants will stay in the clinic for up to 23 days, ensuring comprehensive monitoring and data collection.
Key dates for this study include a start date of July 1, 2025, with the latest update submitted on August 13, 2025. These dates are crucial as they mark the study’s timeline and progress.
The study’s outcomes could influence Pfizer’s stock performance by providing insights into the drug’s potential efficacy and safety, impacting investor confidence. As the study progresses, it may also affect the competitive landscape in the pharmaceutical industry, particularly in the development of cyclin-dependent kinase-2 inhibitors.
The study is currently not yet recruiting, with further details available on the ClinicalTrials portal.